Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor

Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor designed to overcome mechanisms of resistance associated with crizotinib, is approved for the treatment of ALK-positive advanced or metastatic non-small cell lung cancer. After oral administration of single doses of brigatinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Hanley, Michael J., Griffin, Robert J., Zhang, Pingkuan, Venkatakrishnan, Karthik, Sinha, Vikram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386943/
https://www.ncbi.nlm.nih.gov/pubmed/37493887
http://dx.doi.org/10.1007/s40262-023-01284-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386943/
https://www.ncbi.nlm.nih.gov/pubmed/37493887
http://dx.doi.org/10.1007/s40262-023-01284-w

Ejemplares similares